Abstract
SummaryAntibody-drug conjugates (ADCs) are a new class of monoclonal antibodies with the characteritic to specifically target tumor cells and to deliver a cytotoxic drug directly to the target cell thereby minimising side effects and improving the therapeutic index. In recent years, many new ADCs have been approved and are established therapeutic tools in lymphoma treatment.
Funder
Medical University of Graz
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma.ECHELON‑1 Study Group. N Engl J Med. 2022;28;387(4):310–20. Jul.
2. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;20;132(25:2639–42.
3. Rutherford SC, Hongli L, Herrera AF, et al. Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. Presented at ASH 2023. December. San Diego, CA Abstract. 2023;181:9–12.
4. Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;.
5. Borchmann P, Moccia A, Grell R, et al. Treatment related morbidity in patients with classical hodgkin lymphoma: results of the ongoing, randomized phase III HD21 trial by the German Hodgkin Study Group. Blood. 2022;140((suppl 1):771–3.